Old Web
English
Sign In
Acemap
>
authorDetail
>
P. Toquero
P. Toquero
Nivolumab
Medicine
Internal medicine
Pathology
Oncology
5
Papers
7
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
190P Are neutrophil-to-lymphocyte ratio (NLR) and neutrophil count percentage (NCP) predictors of nivolumab outcome and toxicity in NSCLC?
2018
Journal of Thoracic Oncology
J. Rogado
V. Pacheco Barcia
P. Toquero
B Vera
R. Mondejar
N. Romero Laorden
A.I. Ballesteros García
O. Donnay
R. Colomer Bosch
J.M. Sánchez Torres
Show All
Source
Cite
Save
Citations (0)
187P Nivolumab-related immune-related adverse events in advanced NSCLC predict therapeutic objective response
2018
Journal of Thoracic Oncology
J. Rogado
V. Pacheco Barcia
B Vera
P. Toquero
R. Mondejar
A.I. Ballesteros García
O. Donnay
N. Romero Laorden
R. Colomer Bosch
J.M. Sánchez Torres
Show All
Source
Cite
Save
Citations (2)
P2.02-027 Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?
2017
Journal of Thoracic Oncology
J. Rogado
M.D. Fenor de la Maza
V. Pacheco Barcia
J. M. Serra
P. Toquero
B Vera
Ana Isabel Ballesteros
R. Mondejar
O. Donnay
B. Obispo
Ramon Colomer
J.M. Sánchez Torres
Show All
Source
Cite
Save
Citations (5)
P1.01-057 Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
2017
Journal of Thoracic Oncology
J. Rogado
V. Pacheco Barcia
M.D. Fenor de la Maza
J. M. Serra
P. Toquero
B Vera
B. Obispo
R. Mondejar
Ana Isabel Ballesteros
O. Donnay
Ramon Colomer
J.M. Sánchez Torres
Show All
Source
Cite
Save
Citations (0)
Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
2017
J. Rogado
Vilma Pacheco Barcia
M.D. Fenor de la Maza
J.M. Serra
P. Toquero
B Vera
B. Obispo
R. Mondejar
A. Ballesteros
O. Donnay
R. Colomer
J.M. Sánchez Torres
Show All
Source
Cite
Save
Citations (0)
1